Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyDyclonine
Identification
- Name
- Dyclonine
- Accession Number
- DB00645 (APRD00940)
- Type
- Small Molecule
- Groups
- Approved
- Description
Dyclonine is an oral anaesthetic found in Sucrets, an over the counter throat lozenge. It is also found in some varieties of the Cepacol sore throat spray.
- Structure
Structure for DB00645 (Dyclonine)
- Synonyms
- 1-(4-Butoxyphenyl)-3-(1-piperidinyl)-1-propanone
- 2-(1-Piperidyl)ethyl P-butoxyphenyl ketone
- 3-Piperidino-4'-butoxypropiophenone
- 4-Butoxy-beta-piperidinopropiophenone
- 4-N-Butoxy-beta-(1-piperidyl)propiophenone
- 4'-Butoxy-3-piperidinopropiophenone
- Diclonina
- Dyclocaine
- Dyclonin
- Dyclonine
- Dycloninum
- Product Ingredients
Ingredient UNII CAS InChI Key Dyclonine hydrochloride ZEC193879Q 536-43-6 KNZADIMHVBBPOA-UHFFFAOYSA-N - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Cepacol Sore Throat Spray Spray 0.1 % Oral Reckitt Benckiser 1999-07-01 2012-03-23 Canada 
PerioRinse Rinse .1 g/100mL Dental; Oral; Topical; Transmucosal Centura Pharmaceuticals, Inc 2016-06-16 Not applicable US 
Sore Throat Relief Lozenge 3 mg Oral Stanley Pharmaceuticals, A Division Of Vita Health Products Inc. Not applicable Not applicable Canada Sucrets Black Cherry Lozenge 3 mg/1 Oral Insight Pharmaceuticals 2009-06-18 2017-12-22 US Sucrets Childrens Cherry Lozenge 1.2 mg/1 Oral Insight Pharmaceuticals 2009-07-28 2017-12-22 US Sucrets Extra Strength Mint Flav.loz 3mg Lozenge 3 mg Oral Smithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc. 1994-12-31 1998-08-25 Canada Sucrets for Kids Lozenge 1.2 mg Oral Insight Pharmaceuticals 1997-08-15 Not applicable Canada Sucrets for Kids Lozenge 1.2 mg Oral Smithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc. 1992-12-31 1998-08-25 Canada Sucrets MS Wintergreen Lozenge 3 mg/1 Oral Insight Pharmaceuticals 2009-07-28 2018-04-03 US Sucrets Regular Strength Lemon Flav.loz 2mg Lozenge 2 mg Oral Smithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc. 1994-12-31 1998-08-25 Canada - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Ambix First Aid Dyclonine hydrochloride (.005 g/g) + Phenol (.005 g/g) Cream Topical Organics Corporation Of America Dba Ambix Laboratories 2013-08-22 Not applicable US Benzethonium chloride and Dyclonine hydrochloride Dyclonine hydrochloride (.23 mg/29.6mL) + Benzethonium chloride (.06 mg/29.6mL) Liquid Topical Walgreen 2012-01-12 Not applicable US Benzethonium chloride Plus Dyclonine hydrochloride Dyclonine hydrochloride (.75 mg/9mL) + Benzethonium chloride (.2 mg/9mL) Liquid Topical Chain Drug Marketing Association 2017-12-19 Not applicable US Benzethonium chloride Plus Dyclonine hydrochloride Dyclonine hydrochloride (.75 mg/10mL) + Benzethonium chloride (.2 mg/10mL) Liquid Topical CVS Health 2014-07-10 Not applicable US Benzethonium chloride Plus Dyclonine hydrochloride Dyclonine hydrochloride (.75 mg/9mL) + Benzethonium chloride (.2 mg/9mL) Liquid Topical H.E.B. 2017-12-22 Not applicable US Benzethonium chloride Plus Dyclonine hydrochloride Dyclonine hydrochloride (.75 mg/9mL) + Benzethonium chloride (.2 mg/9mL) Liquid Topical L. Perrigo Company 2017-12-20 Not applicable US Benzethonium chloride Plus Dyclonine hydrochloride Dyclonine hydrochloride (.75 mg/10mL) + Benzethonium chloride (.2 mg/10mL) Liquid Topical Harmon Store Inc. 2012-02-14 Not applicable US Benzethonium chloride Plus Dyclonine hydrochloride Dyclonine hydrochloride (.75 mg/9mL) + Benzethonium chloride (.2 mg/9mL) Liquid Topical Kroger 2017-12-06 Not applicable US Benzethonium chloride Plus Dyclonine hydrochloride Dyclonine hydrochloride (.75 mg/9mL) + Benzethonium chloride (.2 mg/9mL) Liquid Topical Harris Teeter 2014-07-10 Not applicable US Benzethonium chloride Plus Dyclonine hydrochloride Dyclonine hydrochloride (.75 mg/9mL) + Benzethonium chloride (.2 mg/9mL) Liquid Topical Value Merchandisers 2017-12-11 Not applicable US - International/Other Brands
- Dyclone (AstraZeneca) / Sucrets (Insight Pharmaceuticals)
- Categories
- UNII
- 078A24Q30O
- CAS number
- 586-60-7
- Weight
- Average: 289.4125
Monoisotopic: 289.204179113 - Chemical Formula
- C18H27NO2
- InChI Key
- BZEWSEKUUPWQDQ-UHFFFAOYSA-N
- InChI
- InChI=1S/C18H27NO2/c1-2-3-15-21-17-9-7-16(8-10-17)18(20)11-14-19-12-5-4-6-13-19/h7-10H,2-6,11-15H2,1H3
- IUPAC Name
- 1-(4-butoxyphenyl)-3-(piperidin-1-yl)propan-1-one
- SMILES
- CCCCOC1=CC=C(C=C1)C(=O)CCN1CCCCC1
Pharmacology
- Indication
Used to provide topical anesthesia of accessible mucous membranes prior to examination, endoscopy or instrumentation, or other procedures involving the esophagus, larynx, mouth, pharynx or throat, respiratory tract or trachea, urinary tract, or vagina. Also used to suppress the gag reflex and/or other laryngeal and esophageal reflexes to facilitate dental examination or procedures (including oral surgery), endoscopy, or intubation. Also used for relief of canker sores, cold sores or fever blister.
- Associated Conditions
- Pharmacodynamics
Dyclonine is an oral anasthetic. If substantial quantities of local anesthetics are absorbed through the mucosa, actions on the central nervous system (CNS) may cause CNS stimulation and/or CNS depression. Actions on the cardiovascular system may cause depression of cardiac conduction and excitability and, with some of these agents, peripheral vasodilation.
- Mechanism of action
Local anesthetics block both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions. This reversibly stabilizes the membrane and inhibits depolarization, resulting in the failure of a propagated action potential and subsequent conduction blockade.
Target Actions Organism ASodium channel protein type 10 subunit alpha inhibitorHuman - Absorption
Readily absorbed through mucous membranes into the systemic circulation. The rate of absorption is influenced by the vascularity or rate of blood flow at the site of application, the total dosage (concentration and volume) administered, and the duration of exposure. Absorption from mucous membranes of the throat or respiratory tract may be especially rapid.
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
Approximately 30 to 60 minutes.
- Clearance
- Not Available
- Toxicity
Symptoms of overdose include cardiovascular system depression, CNS toxicity, and methemoglobinemia.
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 7-Nitroindazole The risk or severity of adverse effects can be increased when Dyclonine is combined with 7-Nitroindazole. Experimental Acepromazine The risk or severity of adverse effects can be increased when Dyclonine is combined with Acepromazine. Approved, Vet Approved Aceprometazine The risk or severity of adverse effects can be increased when Dyclonine is combined with Aceprometazine. Approved Adipiplon The risk or severity of adverse effects can be increased when Dyclonine is combined with Adipiplon. Investigational Agomelatine The risk or severity of adverse effects can be increased when Dyclonine is combined with Agomelatine. Approved, Investigational Alaproclate The risk or severity of adverse effects can be increased when Dyclonine is combined with Alaproclate. Experimental Alfaxalone The risk or severity of adverse effects can be increased when Dyclonine is combined with Alfaxalone. Vet Approved Alfentanil The risk or severity of adverse effects can be increased when Alfentanil is combined with Dyclonine. Approved, Illicit Allopregnanolone The risk or severity of adverse effects can be increased when Dyclonine is combined with Allopregnanolone. Investigational Alphacetylmethadol The risk or severity of adverse effects can be increased when Dyclonine is combined with Alphacetylmethadol. Experimental, Illicit Alphaprodine The risk or severity of adverse effects can be increased when Dyclonine is combined with Alphaprodine. Illicit Alprazolam The risk or severity of adverse effects can be increased when Alprazolam is combined with Dyclonine. Approved, Illicit, Investigational Amikacin The risk or severity of adverse effects can be increased when Dyclonine is combined with Amikacin. Approved, Investigational, Vet Approved Amisulpride The risk or severity of adverse effects can be increased when Dyclonine is combined with Amisulpride. Approved, Investigational Amitriptyline The risk or severity of adverse effects can be increased when Amitriptyline is combined with Dyclonine. Approved Amobarbital The risk or severity of adverse effects can be increased when Amobarbital is combined with Dyclonine. Approved, Illicit Amoxapine The risk or severity of adverse effects can be increased when Amoxapine is combined with Dyclonine. Approved Amperozide The risk or severity of adverse effects can be increased when Dyclonine is combined with Amperozide. Experimental Aripiprazole The risk or severity of adverse effects can be increased when Aripiprazole is combined with Dyclonine. Approved, Investigational Articaine The risk or severity of adverse effects can be increased when Dyclonine is combined with Articaine. Approved Asenapine The risk or severity of adverse effects can be increased when Asenapine is combined with Dyclonine. Approved Azaperone The risk or severity of adverse effects can be increased when Dyclonine is combined with Azaperone. Investigational, Vet Approved Azelastine Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. Approved Baclofen The risk or severity of adverse effects can be increased when Baclofen is combined with Dyclonine. Approved Barbital The risk or severity of adverse effects can be increased when Dyclonine is combined with Barbital. Illicit Benperidol The risk or severity of adverse effects can be increased when Dyclonine is combined with Benperidol. Approved, Investigational Benzphetamine The risk or severity of adverse effects can be increased when Dyclonine is combined with Benzphetamine. Approved, Illicit Benzyl alcohol The risk or severity of adverse effects can be increased when Dyclonine is combined with Benzyl alcohol. Approved Botulinum Toxin Type B The risk or severity of adverse effects can be increased when Dyclonine is combined with Botulinum Toxin Type B. Approved, Investigational Brexpiprazole The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Dyclonine. Approved, Investigational Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Dyclonine. Approved Bromazepam The risk or severity of adverse effects can be increased when Bromazepam is combined with Dyclonine. Approved, Illicit, Investigational Bromisoval The risk or severity of adverse effects can be increased when Dyclonine is combined with Bromisoval. Experimental Bromperidol The risk or severity of adverse effects can be increased when Dyclonine is combined with Bromperidol. Approved, Investigational Brompheniramine The risk or severity of adverse effects can be increased when Brompheniramine is combined with Dyclonine. Approved Brotizolam The risk or severity of adverse effects can be increased when Dyclonine is combined with Brotizolam. Approved, Investigational, Withdrawn Bupivacaine The risk or severity of adverse effects can be increased when Bupivacaine is combined with Dyclonine. Approved, Investigational Buprenorphine Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Approved, Illicit, Investigational, Vet Approved Bupropion The risk or severity of adverse effects can be increased when Dyclonine is combined with Bupropion. Approved Buspirone The risk or severity of adverse effects can be increased when Buspirone is combined with Dyclonine. Approved, Investigational Butabarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Dyclonine. Approved, Illicit Butacaine The risk or severity of adverse effects can be increased when Dyclonine is combined with Butacaine. Vet Approved Butalbital The risk or severity of adverse effects can be increased when Butalbital is combined with Dyclonine. Approved, Illicit Butamben The risk or severity of adverse effects can be increased when Dyclonine is combined with Butamben. Approved, Withdrawn Butethal The risk or severity of adverse effects can be increased when Dyclonine is combined with Butethal. Approved, Illicit Butorphanol The risk or severity of adverse effects can be increased when Butorphanol is combined with Dyclonine. Approved, Illicit, Vet Approved Canertinib The risk or severity of adverse effects can be increased when Dyclonine is combined with Canertinib. Investigational Carbamazepine The risk or severity of adverse effects can be increased when Carbamazepine is combined with Dyclonine. Approved, Investigational Carbinoxamine The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Dyclonine. Approved Carfentanil The risk or severity of adverse effects can be increased when Dyclonine is combined with Carfentanil. Illicit, Investigational, Vet Approved Carisoprodol The risk or severity of adverse effects can be increased when Carisoprodol is combined with Dyclonine. Approved Cetirizine The risk or severity of adverse effects can be increased when Cetirizine is combined with Dyclonine. Approved Chloral hydrate The risk or severity of adverse effects can be increased when Dyclonine is combined with Chloral hydrate. Approved, Illicit, Investigational, Vet Approved Chlordiazepoxide The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dyclonine. Approved, Illicit, Investigational Chlormezanone The risk or severity of adverse effects can be increased when Dyclonine is combined with Chlormezanone. Approved, Investigational, Withdrawn Chloroprocaine The risk or severity of adverse effects can be increased when Dyclonine is combined with Chloroprocaine. Approved Chlorphenamine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dyclonine. Approved Chlorpromazine The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dyclonine. Approved, Investigational, Vet Approved Chlorprothixene The risk or severity of adverse effects can be increased when Dyclonine is combined with Chlorprothixene. Approved, Investigational, Withdrawn Chlorzoxazone The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Dyclonine. Approved Cinchocaine The risk or severity of adverse effects can be increased when Cinchocaine is combined with Dyclonine. Approved, Vet Approved Citalopram The risk or severity of adverse effects can be increased when Dyclonine is combined with Citalopram. Approved Clemastine The risk or severity of adverse effects can be increased when Clemastine is combined with Dyclonine. Approved, Investigational Clidinium The risk or severity of adverse effects can be increased when Clidinium is combined with Dyclonine. Approved Clindamycin The risk or severity of adverse effects can be increased when Dyclonine is combined with Clindamycin. Approved, Vet Approved Clobazam The risk or severity of adverse effects can be increased when Clobazam is combined with Dyclonine. Approved, Illicit clomethiazole The risk or severity of adverse effects can be increased when Dyclonine is combined with clomethiazole. Investigational Clomipramine The risk or severity of adverse effects can be increased when Clomipramine is combined with Dyclonine. Approved, Investigational, Vet Approved Clonazepam The risk or severity of adverse effects can be increased when Clonazepam is combined with Dyclonine. Approved, Illicit Clonidine The risk or severity of adverse effects can be increased when Clonidine is combined with Dyclonine. Approved Clopenthixol The risk or severity of adverse effects can be increased when Dyclonine is combined with Clopenthixol. Experimental Clorazepate The risk or severity of adverse effects can be increased when Clorazepate is combined with Dyclonine. Approved, Illicit Clothiapine The risk or severity of adverse effects can be increased when Dyclonine is combined with Clothiapine. Experimental Clozapine The risk or severity of adverse effects can be increased when Clozapine is combined with Dyclonine. Approved Cocaine The risk or severity of adverse effects can be increased when Dyclonine is combined with Cocaine. Approved, Illicit Codeine The risk or severity of adverse effects can be increased when Codeine is combined with Dyclonine. Approved, Illicit Cyclizine The risk or severity of adverse effects can be increased when Cyclizine is combined with Dyclonine. Approved Cyclobenzaprine The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dyclonine. Approved Cyclopropane The risk or severity of adverse effects can be increased when Dyclonine is combined with Cyclopropane. Experimental Cyclosporine The risk or severity of adverse effects can be increased when Dyclonine is combined with Cyclosporine. Approved, Investigational, Vet Approved Cyproheptadine The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Dyclonine. Approved Dantrolene The risk or severity of adverse effects can be increased when Dantrolene is combined with Dyclonine. Approved, Investigational Dapiprazole The risk or severity of adverse effects can be increased when Dapiprazole is combined with Dyclonine. Approved Dapoxetine The risk or severity of adverse effects can be increased when Dyclonine is combined with Dapoxetine. Investigational Deramciclane The risk or severity of adverse effects can be increased when Dyclonine is combined with Deramciclane. Investigational Desflurane The risk or severity of adverse effects can be increased when Desflurane is combined with Dyclonine. Approved Desipramine The risk or severity of adverse effects can be increased when Desipramine is combined with Dyclonine. Approved, Investigational Desloratadine The risk or severity of adverse effects can be increased when Desloratadine is combined with Dyclonine. Approved, Investigational Desvenlafaxine The risk or severity of adverse effects can be increased when Dyclonine is combined with Desvenlafaxine. Approved, Investigational Detomidine The risk or severity of adverse effects can be increased when Dyclonine is combined with Detomidine. Vet Approved Dexbrompheniramine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dyclonine. Approved Dexmedetomidine The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dyclonine. Approved, Vet Approved Dextromoramide The risk or severity of adverse effects can be increased when Dyclonine is combined with Dextromoramide. Experimental, Illicit Dextropropoxyphene The risk or severity of adverse effects can be increased when Dyclonine is combined with Dextropropoxyphene. Approved, Illicit, Investigational, Withdrawn Dezocine The risk or severity of adverse effects can be increased when Dyclonine is combined with Dezocine. Approved, Investigational Diazepam The risk or severity of adverse effects can be increased when Diazepam is combined with Dyclonine. Approved, Illicit, Investigational, Vet Approved Diethyl ether The risk or severity of adverse effects can be increased when Dyclonine is combined with Diethyl ether. Experimental Difenoxin The risk or severity of adverse effects can be increased when Difenoxin is combined with Dyclonine. Approved, Illicit Dihydrocodeine The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Dyclonine. Approved, Illicit Dihydroetorphine The risk or severity of adverse effects can be increased when Dyclonine is combined with Dihydroetorphine. Experimental, Illicit Dihydromorphine The risk or severity of adverse effects can be increased when Dyclonine is combined with Dihydromorphine. Experimental, Illicit Dimenhydrinate The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Dyclonine. Approved Diphenhydramine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dyclonine. Approved, Investigational Diphenoxylate The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dyclonine. Approved, Illicit Dixyrazine The risk or severity of adverse effects can be increased when Dyclonine is combined with Dixyrazine. Experimental Doramectin The risk or severity of adverse effects can be increased when Dyclonine is combined with Doramectin. Vet Approved Dotarizine The risk or severity of adverse effects can be increased when Dyclonine is combined with Dotarizine. Investigational Doxepin The risk or severity of adverse effects can be increased when Doxepin is combined with Dyclonine. Approved, Investigational Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dyclonine. Approved, Vet Approved DPDPE The risk or severity of adverse effects can be increased when Dyclonine is combined with DPDPE. Experimental Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Dyclonine. Approved, Illicit Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Dyclonine. Approved, Vet Approved Drotebanol The risk or severity of adverse effects can be increased when Dyclonine is combined with Drotebanol. Experimental, Illicit Duloxetine The risk or severity of adverse effects can be increased when Dyclonine is combined with Duloxetine. Approved Ecgonine The risk or severity of adverse effects can be increased when Dyclonine is combined with Ecgonine. Experimental, Illicit Ecopipam The risk or severity of adverse effects can be increased when Dyclonine is combined with Ecopipam. Investigational Efavirenz The risk or severity of adverse effects can be increased when Efavirenz is combined with Dyclonine. Approved, Investigational Eltanolone The risk or severity of adverse effects can be increased when Dyclonine is combined with Eltanolone. Investigational Enflurane The risk or severity of adverse effects can be increased when Enflurane is combined with Dyclonine. Approved, Investigational, Vet Approved Entacapone The risk or severity of adverse effects can be increased when Entacapone is combined with Dyclonine. Approved, Investigational Eperisone The risk or severity of adverse effects can be increased when Dyclonine is combined with Eperisone. Approved, Investigational Escitalopram The risk or severity of adverse effects can be increased when Dyclonine is combined with Escitalopram. Approved, Investigational Estazolam The risk or severity of adverse effects can be increased when Estazolam is combined with Dyclonine. Approved, Illicit Eszopiclone The risk or severity of adverse effects can be increased when Eszopiclone is combined with Dyclonine. Approved, Investigational Ethanol Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. Approved Ethchlorvynol The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dyclonine. Approved, Illicit, Withdrawn Ethosuximide The risk or severity of adverse effects can be increased when Ethosuximide is combined with Dyclonine. Approved Ethotoin The risk or severity of adverse effects can be increased when Ethotoin is combined with Dyclonine. Approved Ethyl carbamate The risk or severity of adverse effects can be increased when Dyclonine is combined with Ethyl carbamate. Withdrawn Ethyl chloride The risk or severity of adverse effects can be increased when Dyclonine is combined with Ethyl chloride. Approved, Experimental, Investigational Ethyl loflazepate The risk or severity of adverse effects can be increased when Dyclonine is combined with Ethyl loflazepate. Approved, Illicit Ethylmorphine The risk or severity of adverse effects can be increased when Dyclonine is combined with Ethylmorphine. Approved, Illicit Etidocaine The risk or severity of adverse effects can be increased when Dyclonine is combined with Etidocaine. Approved Etifoxine The risk or severity of adverse effects can be increased when Dyclonine is combined with Etifoxine. Investigational, Withdrawn Etizolam The risk or severity of adverse effects can be increased when Dyclonine is combined with Etizolam. Approved Etomidate The risk or severity of adverse effects can be increased when Etomidate is combined with Dyclonine. Approved Etoperidone The risk or severity of adverse effects can be increased when Dyclonine is combined with Etoperidone. Withdrawn Etorphine The risk or severity of adverse effects can be increased when Dyclonine is combined with Etorphine. Illicit, Vet Approved Ezogabine The risk or severity of adverse effects can be increased when Ezogabine is combined with Dyclonine. Approved, Investigational Felbamate The risk or severity of adverse effects can be increased when Felbamate is combined with Dyclonine. Approved Fencamfamine The risk or severity of adverse effects can be increased when Dyclonine is combined with Fencamfamine. Approved, Illicit, Withdrawn Fentanyl The risk or severity of adverse effects can be increased when Fentanyl is combined with Dyclonine. Approved, Illicit, Investigational, Vet Approved Fexofenadine The risk or severity of adverse effects can be increased when Fexofenadine is combined with Dyclonine. Approved, Investigational Flibanserin The risk or severity of adverse effects can be increased when Flibanserin is combined with Dyclonine. Approved, Investigational Fluanisone The risk or severity of adverse effects can be increased when Dyclonine is combined with Fluanisone. Experimental Fludiazepam The risk or severity of adverse effects can be increased when Dyclonine is combined with Fludiazepam. Approved, Illicit Flunarizine The risk or severity of adverse effects can be increased when Flunarizine is combined with Dyclonine. Approved Flunitrazepam The risk or severity of adverse effects can be increased when Dyclonine is combined with Flunitrazepam. Approved, Illicit Fluoxetine The risk or severity of adverse effects can be increased when Dyclonine is combined with Fluoxetine. Approved, Vet Approved Flupentixol The risk or severity of adverse effects can be increased when Flupentixol is combined with Dyclonine. Approved, Investigational, Withdrawn Fluphenazine The risk or severity of adverse effects can be increased when Fluphenazine is combined with Dyclonine. Approved Flurazepam The risk or severity of adverse effects can be increased when Flurazepam is combined with Dyclonine. Approved, Illicit, Investigational Fluspirilene The risk or severity of adverse effects can be increased when Dyclonine is combined with Fluspirilene. Approved, Investigational Fluticasone propionate The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Dyclonine. Approved Fluvoxamine The risk or severity of adverse effects can be increased when Dyclonine is combined with Fluvoxamine. Approved, Investigational Fosphenytoin The risk or severity of adverse effects can be increased when Fosphenytoin is combined with Dyclonine. Approved, Investigational Fospropofol The risk or severity of adverse effects can be increased when Dyclonine is combined with Fospropofol. Approved, Illicit, Investigational Gabapentin The risk or severity of adverse effects can be increased when Gabapentin is combined with Dyclonine. Approved, Investigational Gabapentin Enacarbil The risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Dyclonine. Approved, Investigational Gamma Hydroxybutyric Acid The risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Dyclonine. Approved, Illicit, Investigational Gepirone The risk or severity of adverse effects can be increased when Dyclonine is combined with Gepirone. Investigational Glutethimide The risk or severity of adverse effects can be increased when Dyclonine is combined with Glutethimide. Approved, Illicit Guanfacine The risk or severity of adverse effects can be increased when Guanfacine is combined with Dyclonine. Approved, Investigational Halazepam The risk or severity of adverse effects can be increased when Dyclonine is combined with Halazepam. Approved, Illicit, Withdrawn Haloperidol The risk or severity of adverse effects can be increased when Haloperidol is combined with Dyclonine. Approved Halothane The risk or severity of adverse effects can be increased when Dyclonine is combined with Halothane. Approved, Vet Approved Heroin The risk or severity of adverse effects can be increased when Dyclonine is combined with Heroin. Approved, Illicit, Investigational Hexobarbital The risk or severity of adverse effects can be increased when Dyclonine is combined with Hexobarbital. Approved Hyaluronidase The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Dyclonine. Approved, Investigational Hydrocodone Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. Approved, Illicit Hydromorphone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dyclonine. Approved, Illicit Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dyclonine. Approved Iloperidone The risk or severity of adverse effects can be increased when Iloperidone is combined with Dyclonine. Approved Imipramine The risk or severity of adverse effects can be increased when Imipramine is combined with Dyclonine. Approved Indalpine The risk or severity of adverse effects can be increased when Dyclonine is combined with Indalpine. Investigational, Withdrawn Indiplon The risk or severity of adverse effects can be increased when Dyclonine is combined with Indiplon. Investigational Isoflurane The risk or severity of adverse effects can be increased when Isoflurane is combined with Dyclonine. Approved, Vet Approved Ketamine The risk or severity of adverse effects can be increased when Ketamine is combined with Dyclonine. Approved, Vet Approved Ketazolam The risk or severity of adverse effects can be increased when Dyclonine is combined with Ketazolam. Approved Ketobemidone The risk or severity of adverse effects can be increased when Dyclonine is combined with Ketobemidone. Approved, Investigational Lamotrigine The risk or severity of adverse effects can be increased when Lamotrigine is combined with Dyclonine. Approved, Investigational Levetiracetam The risk or severity of adverse effects can be increased when Levetiracetam is combined with Dyclonine. Approved, Investigational Levobupivacaine The risk or severity of adverse effects can be increased when Dyclonine is combined with Levobupivacaine. Approved, Investigational Levocabastine The risk or severity of adverse effects can be increased when Dyclonine is combined with Levocabastine. Approved, Investigational Levocetirizine The risk or severity of adverse effects can be increased when Levocetirizine is combined with Dyclonine. Approved Levodopa The risk or severity of adverse effects can be increased when Levodopa is combined with Dyclonine. Approved Levomethadyl Acetate The risk or severity of adverse effects can be increased when Dyclonine is combined with Levomethadyl Acetate. Approved, Investigational Levomilnacipran The risk or severity of adverse effects can be increased when Dyclonine is combined with Levomilnacipran. Approved, Investigational Levorphanol The risk or severity of adverse effects can be increased when Levorphanol is combined with Dyclonine. Approved Lithium cation The risk or severity of adverse effects can be increased when Dyclonine is combined with Lithium. Experimental Lofentanil The risk or severity of adverse effects can be increased when Dyclonine is combined with Lofentanil. Illicit Lofexidine The therapeutic efficacy of Dyclonine can be increased when used in combination with Lofexidine. Approved, Investigational Loprazolam The risk or severity of adverse effects can be increased when Dyclonine is combined with Loprazolam. Experimental Loratadine The risk or severity of adverse effects can be increased when Loratadine is combined with Dyclonine. Approved, Investigational Lorazepam The risk or severity of adverse effects can be increased when Lorazepam is combined with Dyclonine. Approved Lormetazepam The risk or severity of adverse effects can be increased when Dyclonine is combined with Lormetazepam. Approved Loxapine The risk or severity of adverse effects can be increased when Loxapine is combined with Dyclonine. Approved Lurasidone The risk or severity of adverse effects can be increased when Lurasidone is combined with Dyclonine. Approved, Investigational Magnesium carbonate The risk or severity of adverse effects can be increased when Dyclonine is combined with Magnesium carbonate. Approved, Investigational Magnesium citrate The risk or severity of adverse effects can be increased when Dyclonine is combined with Magnesium citrate. Approved Magnesium hydroxide The risk or severity of adverse effects can be increased when Dyclonine is combined with Magnesium hydroxide. Approved, Investigational Magnesium sulfate The therapeutic efficacy of Dyclonine can be increased when used in combination with Magnesium sulfate. Approved, Investigational, Vet Approved Magnesium Trisilicate The risk or severity of adverse effects can be increased when Dyclonine is combined with Magnesium Trisilicate. Approved Maprotiline The risk or severity of adverse effects can be increased when Maprotiline is combined with Dyclonine. Approved, Investigational Mebicar The risk or severity of adverse effects can be increased when Dyclonine is combined with Mebicar. Experimental Meclizine The risk or severity of adverse effects can be increased when Meclizine is combined with Dyclonine. Approved Medazepam The risk or severity of adverse effects can be increased when Dyclonine is combined with Medazepam. Experimental Medetomidine The risk or severity of adverse effects can be increased when Dyclonine is combined with Medetomidine. Vet Approved Melatonin The risk or severity of adverse effects can be increased when Dyclonine is combined with Melatonin. Approved, Nutraceutical, Vet Approved Melperone The risk or severity of adverse effects can be increased when Dyclonine is combined with Melperone. Approved, Investigational Mepivacaine The risk or severity of adverse effects can be increased when Dyclonine is combined with Mepivacaine. Approved, Vet Approved Meprobamate The risk or severity of adverse effects can be increased when Meprobamate is combined with Dyclonine. Approved, Illicit Meptazinol The risk or severity of adverse effects can be increased when Dyclonine is combined with Meptazinol. Experimental Mesoridazine The risk or severity of adverse effects can be increased when Dyclonine is combined with Mesoridazine. Approved, Investigational Metaxalone The risk or severity of adverse effects can be increased when Metaxalone is combined with Dyclonine. Approved Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Dyclonine. Approved Methadyl Acetate The risk or severity of adverse effects can be increased when Dyclonine is combined with Methadyl Acetate. Approved, Illicit Methapyrilene The risk or severity of adverse effects can be increased when Dyclonine is combined with Methapyrilene. Withdrawn Methaqualone The risk or severity of adverse effects can be increased when Dyclonine is combined with Methaqualone. Illicit, Withdrawn Methocarbamol The risk or severity of adverse effects can be increased when Methocarbamol is combined with Dyclonine. Approved, Vet Approved Methohexital The risk or severity of adverse effects can be increased when Methohexital is combined with Dyclonine. Approved Methotrimeprazine Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. Approved, Investigational Methoxyflurane The risk or severity of adverse effects can be increased when Dyclonine is combined with Methoxyflurane. Approved, Investigational, Vet Approved Methsuximide The risk or severity of adverse effects can be increased when Methsuximide is combined with Dyclonine. Approved Methylecgonine The risk or severity of adverse effects can be increased when Dyclonine is combined with Methylecgonine. Experimental Methylphenobarbital The risk or severity of adverse effects can be increased when Dyclonine is combined with Methylphenobarbital. Approved Metyrosine Dyclonine may increase the sedative activities of Metyrosine. Approved Midazolam The risk or severity of adverse effects can be increased when Midazolam is combined with Dyclonine. Approved, Illicit Milnacipran The risk or severity of adverse effects can be increased when Dyclonine is combined with Milnacipran. Approved, Investigational Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Dyclonine. Approved, Investigational Mirtazapine Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. Approved Molindone The risk or severity of adverse effects can be increased when Dyclonine is combined with Molindone. Approved Morphine The risk or severity of adverse effects can be increased when Morphine is combined with Dyclonine. Approved, Investigational Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Dyclonine. Approved, Investigational Nalbuphine The risk or severity of adverse effects can be increased when Nalbuphine is combined with Dyclonine. Approved Nefazodone The risk or severity of adverse effects can be increased when Dyclonine is combined with Nefazodone. Approved, Withdrawn Neomycin The risk or severity of adverse effects can be increased when Dyclonine is combined with Neomycin. Approved, Vet Approved Nitrazepam The risk or severity of adverse effects can be increased when Nitrazepam is combined with Dyclonine. Approved Nitrous oxide The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Dyclonine. Approved, Vet Approved Nordazepam The risk or severity of adverse effects can be increased when Dyclonine is combined with Nordazepam. Approved Norflurane The risk or severity of adverse effects can be increased when Dyclonine is combined with Norflurane. Approved, Investigational Normethadone The risk or severity of adverse effects can be increased when Dyclonine is combined with Normethadone. Approved, Illicit Nortriptyline The risk or severity of adverse effects can be increased when Nortriptyline is combined with Dyclonine. Approved Olanzapine The risk or severity of adverse effects can be increased when Olanzapine is combined with Dyclonine. Approved, Investigational Olopatadine The risk or severity of adverse effects can be increased when Olopatadine is combined with Dyclonine. Approved Ondansetron The risk or severity of adverse effects can be increased when Dyclonine is combined with Ondansetron. Approved Opium The risk or severity of adverse effects can be increased when Dyclonine is combined with Opium. Approved, Illicit Orphenadrine Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. Approved Osanetant The risk or severity of adverse effects can be increased when Dyclonine is combined with Osanetant. Investigational Oxazepam The risk or severity of adverse effects can be increased when Oxazepam is combined with Dyclonine. Approved Oxprenolol The risk or severity of adverse effects can be increased when Dyclonine is combined with Oxprenolol. Approved Oxybuprocaine The risk or severity of adverse effects can be increased when Dyclonine is combined with Oxybuprocaine. Approved, Investigational Oxycodone The risk or severity of adverse effects can be increased when Oxycodone is combined with Dyclonine. Approved, Illicit, Investigational Oxymorphone The risk or severity of adverse effects can be increased when Oxymorphone is combined with Dyclonine. Approved, Investigational, Vet Approved Paliperidone The risk or severity of adverse effects can be increased when Paliperidone is combined with Dyclonine. Approved Paraldehyde Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. Approved, Investigational Paromomycin The risk or severity of adverse effects can be increased when Dyclonine is combined with Paromomycin. Approved, Investigational Paroxetine The risk or severity of adverse effects can be increased when Dyclonine is combined with Paroxetine. Approved, Investigational Penfluridol The risk or severity of adverse effects can be increased when Dyclonine is combined with Penfluridol. Experimental Pentazocine The risk or severity of adverse effects can be increased when Pentazocine is combined with Dyclonine. Approved, Vet Approved Pentobarbital The risk or severity of adverse effects can be increased when Pentobarbital is combined with Dyclonine. Approved, Investigational, Vet Approved Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Dyclonine. Approved Perazine The risk or severity of adverse effects can be increased when Dyclonine is combined with Perazine. Approved, Investigational Perospirone The risk or severity of adverse effects can be increased when Dyclonine is combined with Perospirone. Approved Perphenazine The risk or severity of adverse effects can be increased when Perphenazine is combined with Dyclonine. Approved Pethidine The risk or severity of adverse effects can be increased when Pethidine is combined with Dyclonine. Approved Phenazocine The risk or severity of adverse effects can be increased when Dyclonine is combined with Phenazocine. Experimental Phenibut The risk or severity of adverse effects can be increased when Dyclonine is combined with Phenibut. Experimental Phenobarbital The risk or severity of adverse effects can be increased when Phenobarbital is combined with Dyclonine. Approved, Investigational Phenoperidine The risk or severity of adverse effects can be increased when Dyclonine is combined with Phenoperidine. Experimental Phenoxyethanol The risk or severity of adverse effects can be increased when Dyclonine is combined with Phenoxyethanol. Approved Phenytoin The risk or severity of adverse effects can be increased when Phenytoin is combined with Dyclonine. Approved, Vet Approved Pimozide The risk or severity of adverse effects can be increased when Pimozide is combined with Dyclonine. Approved Pipamperone The risk or severity of adverse effects can be increased when Dyclonine is combined with Pipamperone. Approved, Investigational Pipotiazine The risk or severity of adverse effects can be increased when Pipotiazine is combined with Dyclonine. Approved, Investigational Piritramide The risk or severity of adverse effects can be increased when Dyclonine is combined with Piritramide. Approved, Investigational Pizotifen The risk or severity of adverse effects can be increased when Pizotifen is combined with Dyclonine. Approved Polymyxin B Sulfate The risk or severity of adverse effects can be increased when Dyclonine is combined with Polymyxin B Sulfate. Approved, Vet Approved Pomalidomide The risk or severity of adverse effects can be increased when Pomalidomide is combined with Dyclonine. Approved Pramipexole Dyclonine may increase the sedative activities of Pramipexole. Approved, Investigational Prazepam The risk or severity of adverse effects can be increased when Dyclonine is combined with Prazepam. Approved, Illicit Pregabalin The therapeutic efficacy of Dyclonine can be increased when used in combination with Pregabalin. Approved, Illicit, Investigational Prilocaine The risk or severity of adverse effects can be increased when Dyclonine is combined with Prilocaine. Approved Primidone The risk or severity of adverse effects can be increased when Primidone is combined with Dyclonine. Approved, Vet Approved Procaine The risk or severity of adverse effects can be increased when Dyclonine is combined with Procaine. Approved, Investigational, Vet Approved Prochlorperazine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dyclonine. Approved, Vet Approved Promazine The risk or severity of adverse effects can be increased when Promazine is combined with Dyclonine. Approved, Vet Approved Promethazine The risk or severity of adverse effects can be increased when Promethazine is combined with Dyclonine. Approved, Investigational Propanidid The risk or severity of adverse effects can be increased when Dyclonine is combined with Propanidid. Experimental Proparacaine The risk or severity of adverse effects can be increased when Dyclonine is combined with Proparacaine. Approved, Vet Approved Propofol The risk or severity of adverse effects can be increased when Propofol is combined with Dyclonine. Approved, Investigational, Vet Approved Propoxycaine The risk or severity of adverse effects can be increased when Dyclonine is combined with Propoxycaine. Approved Protriptyline The risk or severity of adverse effects can be increased when Protriptyline is combined with Dyclonine. Approved Proxibarbal The risk or severity of adverse effects can be increased when Dyclonine is combined with Proxibarbal. Experimental PSD502 The risk or severity of adverse effects can be increased when Dyclonine is combined with PSD502. Investigational Pseudoephedrine The risk or severity of adverse effects can be increased when Dyclonine is combined with Pseudoephedrine. Approved Pyrantel The risk or severity of adverse effects can be increased when Dyclonine is combined with Pyrantel. Approved, Vet Approved Quazepam The risk or severity of adverse effects can be increased when Quazepam is combined with Dyclonine. Approved, Illicit Quetiapine The risk or severity of adverse effects can be increased when Quetiapine is combined with Dyclonine. Approved Quinisocaine The risk or severity of adverse effects can be increased when Dyclonine is combined with Quinisocaine. Experimental Raclopride The risk or severity of adverse effects can be increased when Dyclonine is combined with Raclopride. Investigational Ramelteon The risk or severity of adverse effects can be increased when Ramelteon is combined with Dyclonine. Approved, Investigational Remifentanil The risk or severity of adverse effects can be increased when Remifentanil is combined with Dyclonine. Approved Remoxipride The risk or severity of adverse effects can be increased when Remoxipride is combined with Dyclonine. Approved, Withdrawn Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Dyclonine. Approved, Investigational Risperidone The risk or severity of adverse effects can be increased when Risperidone is combined with Dyclonine. Approved, Investigational Ritanserin The risk or severity of adverse effects can be increased when Dyclonine is combined with Ritanserin. Investigational Rizatriptan The risk or severity of adverse effects can be increased when Dyclonine is combined with Rizatriptan. Approved Romifidine The risk or severity of adverse effects can be increased when Dyclonine is combined with Romifidine. Vet Approved Ropinirole Dyclonine may increase the sedative activities of Ropinirole. Approved, Investigational Ropivacaine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Dyclonine. Approved Rotigotine Dyclonine may increase the sedative activities of Rotigotine. Approved Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Dyclonine. Approved Scopolamine The risk or severity of adverse effects can be increased when Scopolamine is combined with Dyclonine. Approved, Investigational Secobarbital The risk or severity of adverse effects can be increased when Secobarbital is combined with Dyclonine. Approved, Vet Approved Sepranolone The risk or severity of adverse effects can be increased when Dyclonine is combined with Sepranolone. Investigational Sertindole The risk or severity of adverse effects can be increased when Dyclonine is combined with Sertindole. Approved, Investigational, Withdrawn Sertraline The risk or severity of adverse effects can be increased when Dyclonine is combined with Sertraline. Approved Sevoflurane The risk or severity of adverse effects can be increased when Sevoflurane is combined with Dyclonine. Approved, Vet Approved Sodium oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Dyclonine. Approved Stiripentol The risk or severity of adverse effects can be increased when Stiripentol is combined with Dyclonine. Approved Sufentanil The risk or severity of adverse effects can be increased when Sufentanil is combined with Dyclonine. Approved, Investigational Sulpiride The risk or severity of adverse effects can be increased when Sulpiride is combined with Dyclonine. Approved, Investigational Sultopride The risk or severity of adverse effects can be increased when Dyclonine is combined with Sultopride. Experimental Sumatriptan The risk or severity of adverse effects can be increased when Dyclonine is combined with Sumatriptan. Approved, Investigational Suvorexant Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. Approved, Investigational Tandospirone The risk or severity of adverse effects can be increased when Dyclonine is combined with Tandospirone. Investigational Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Dyclonine. Approved Tasimelteon The risk or severity of adverse effects can be increased when Tasimelteon is combined with Dyclonine. Approved, Investigational Technetium Tc-99m tilmanocept Dyclonine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent. Approved, Investigational Temazepam The risk or severity of adverse effects can be increased when Temazepam is combined with Dyclonine. Approved, Investigational Tetrabenazine The risk or severity of adverse effects can be increased when Tetrabenazine is combined with Dyclonine. Approved, Investigational Tetracaine The risk or severity of adverse effects can be increased when Dyclonine is combined with Tetracaine. Approved, Vet Approved Tetracycline The risk or severity of adverse effects can be increased when Dyclonine is combined with Tetracycline. Approved, Vet Approved Tetrahydropalmatine The risk or severity of adverse effects can be increased when Dyclonine is combined with Tetrahydropalmatine. Investigational Tetrodotoxin The risk or severity of adverse effects can be increased when Dyclonine is combined with Tetrodotoxin. Investigational Thalidomide Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. Approved, Investigational, Withdrawn Thiamylal The risk or severity of adverse effects can be increased when Dyclonine is combined with Thiamylal. Approved, Vet Approved Thiopental The risk or severity of adverse effects can be increased when Thiopental is combined with Dyclonine. Approved, Vet Approved Thioridazine The risk or severity of adverse effects can be increased when Thioridazine is combined with Dyclonine. Approved, Withdrawn Thiothixene The risk or severity of adverse effects can be increased when Thiothixene is combined with Dyclonine. Approved Tiagabine The risk or severity of adverse effects can be increased when Tiagabine is combined with Dyclonine. Approved, Investigational Tiapride The risk or severity of adverse effects can be increased when Dyclonine is combined with Tiapride. Approved, Investigational Tiletamine The risk or severity of adverse effects can be increased when Dyclonine is combined with Tiletamine. Vet Approved Tilidine The risk or severity of adverse effects can be increased when Dyclonine is combined with Tilidine. Experimental Tizanidine The risk or severity of adverse effects can be increased when Tizanidine is combined with Dyclonine. Approved, Investigational Tolcapone The risk or severity of adverse effects can be increased when Tolcapone is combined with Dyclonine. Approved, Withdrawn Topiramate The risk or severity of adverse effects can be increased when Topiramate is combined with Dyclonine. Approved Tramadol The risk or severity of adverse effects can be increased when Tramadol is combined with Dyclonine. Approved, Investigational Tranylcypromine The risk or severity of adverse effects can be increased when Dyclonine is combined with Tranylcypromine. Approved, Investigational Trazodone The risk or severity of adverse effects can be increased when Dyclonine is combined with Trazodone. Approved, Investigational Triazolam The risk or severity of adverse effects can be increased when Triazolam is combined with Dyclonine. Approved, Investigational Tricaine methanesulfonate The risk or severity of adverse effects can be increased when Dyclonine is combined with Tricaine methanesulfonate. Vet Approved Trichloroethylene The risk or severity of adverse effects can be increased when Dyclonine is combined with Trichloroethylene. Approved Trifluoperazine The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dyclonine. Approved, Investigational Trifluperidol The risk or severity of adverse effects can be increased when Dyclonine is combined with Trifluperidol. Experimental Triflupromazine The risk or severity of adverse effects can be increased when Triflupromazine is combined with Dyclonine. Approved, Vet Approved Trimethadione The risk or severity of adverse effects can be increased when Dyclonine is combined with Trimethadione. Approved Trimipramine The risk or severity of adverse effects can be increased when Trimipramine is combined with Dyclonine. Approved Triprolidine The risk or severity of adverse effects can be increased when Triprolidine is combined with Dyclonine. Approved Valproic Acid The risk or severity of adverse effects can be increased when Valproic Acid is combined with Dyclonine. Approved, Investigational Vancomycin The risk or severity of adverse effects can be increased when Dyclonine is combined with Vancomycin. Approved Vecuronium The risk or severity of adverse effects can be increased when Dyclonine is combined with Vecuronium. Approved Venlafaxine The risk or severity of adverse effects can be increased when Dyclonine is combined with Venlafaxine. Approved Veralipride The risk or severity of adverse effects can be increased when Dyclonine is combined with Veralipride. Experimental Vigabatrin The risk or severity of adverse effects can be increased when Vigabatrin is combined with Dyclonine. Approved Vinpocetine The risk or severity of adverse effects can be increased when Dyclonine is combined with Vinpocetine. Investigational Vinyl ether The risk or severity of adverse effects can be increased when Dyclonine is combined with Vinyl ether. Experimental Vortioxetine The risk or severity of adverse effects can be increased when Dyclonine is combined with Vortioxetine. Approved, Investigational Xenon The risk or severity of adverse effects can be increased when Dyclonine is combined with Xenon. Experimental Xylazine The risk or severity of adverse effects can be increased when Dyclonine is combined with Xylazine. Vet Approved Zaleplon The risk or severity of adverse effects can be increased when Zaleplon is combined with Dyclonine. Approved, Illicit, Investigational Ziconotide The risk or severity of adverse effects can be increased when Ziconotide is combined with Dyclonine. Approved Zimelidine The risk or severity of adverse effects can be increased when Dyclonine is combined with Zimelidine. Withdrawn Ziprasidone The risk or severity of adverse effects can be increased when Ziprasidone is combined with Dyclonine. Approved Zolazepam The risk or severity of adverse effects can be increased when Dyclonine is combined with Zolazepam. Vet Approved Zolmitriptan The risk or severity of adverse effects can be increased when Dyclonine is combined with Zolmitriptan. Approved, Investigational Zolpidem Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. Approved Zonisamide The risk or severity of adverse effects can be increased when Zonisamide is combined with Dyclonine. Approved, Investigational Zopiclone The risk or severity of adverse effects can be increased when Zopiclone is combined with Dyclonine. Approved Zotepine The risk or severity of adverse effects can be increased when Dyclonine is combined with Zotepine. Approved, Investigational, Withdrawn Zuclopenthixol The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Dyclonine. Approved, Investigational - Food Interactions
- Not Available
References
- Synthesis Reference
Tianjiang Sun, Xiaohong Gu, Hongguo Lu, Min Chen, "Oral Preparation of Dyclonine Hydrochloride." U.S. Patent US20080200506, issued August 21, 2008.
US20080200506- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0014783
- KEGG Compound
- C07881
- PubChem Compound
- 3180
- PubChem Substance
- 46506697
- ChemSpider
- 3068
- ChEBI
- 4724
- ChEMBL
- CHEMBL1201217
- Therapeutic Targets Database
- DAP000509
- PharmGKB
- PA164748037
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Dyclonine
- ATC Codes
- N01BX02 — DyclonineR02AD04 — Dyclonine
- AHFS Codes
- 52:16.00 — Local Anesthetics
- MSDS
- Download (73.4 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1, 2 Completed Treatment Gingival Inflammation 1
Pharmacoeconomics
- Manufacturers
- Astrazeneca lp
- Packagers
- Gallipot
- Long Wing International Inc.
- Dosage forms
Form Route Strength Cream Topical Liquid Topical Liquid Oral Spray Oral 0.1 % Rinse Dental; Oral; Topical; Transmucosal .1 g/100mL Lozenge Oral 3 mg/1 Lozenge Oral 1.2 mg/1 Lozenge Oral Lozenge Oral 1.2 mg Lozenge Oral 2 mg Lozenge Oral 3 mg Aerosol Oral .1 % Lozenge Oral 2 mg/1 Gel Topical - Prices
Unit description Cost Unit Dyclonine hcl powder 4.9USD g DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 174-175 Bockstahler, E.R.; U.S.Patent 2,771,391; November 20,1956; assigned to Allied Laboratories, Inc. Florestano, H.J., Jeffries, S.F., Osborne, C.E. and Bahler, M.E.; U.S. Patent 2,868,689; January 13, 1959; assigned to Allied Laboratories, Inc. water solubility Soluble (HCl salt) Not Available logP 3.7 Not Available - Predicted Properties
Property Value Source Water Solubility 0.046 mg/mL ALOGPS logP 4.11 ALOGPS logP 3.68 ChemAxon logS -3.8 ALOGPS pKa (Strongest Acidic) 15.88 ChemAxon pKa (Strongest Basic) 8.36 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 29.54 Å2 ChemAxon Rotatable Bond Count 8 ChemAxon Refractivity 87.07 m3·mol-1 ChemAxon Polarizability 35.14 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.9856 Caco-2 permeable + 0.7155 P-glycoprotein substrate Substrate 0.7596 P-glycoprotein inhibitor I Inhibitor 0.8077 P-glycoprotein inhibitor II Non-inhibitor 0.6392 Renal organic cation transporter Inhibitor 0.7801 CYP450 2C9 substrate Non-substrate 0.8107 CYP450 2D6 substrate Non-substrate 0.5142 CYP450 3A4 substrate Substrate 0.5313 CYP450 1A2 substrate Inhibitor 0.8914 CYP450 2C9 inhibitor Inhibitor 0.793 CYP450 2D6 inhibitor Inhibitor 0.8932 CYP450 2C19 inhibitor Non-inhibitor 0.9026 CYP450 3A4 inhibitor Non-inhibitor 0.8574 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.5388 Ames test Non AMES toxic 0.7961 Carcinogenicity Non-carcinogens 0.8823 Biodegradation Not ready biodegradable 0.7106 Rat acute toxicity 2.3661 LD50, mol/kg Not applicable hERG inhibition (predictor I) Strong inhibitor 0.8071 hERG inhibition (predictor II) Inhibitor 0.6351
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as alkyl-phenylketones. These are aromatic compounds containing a ketone substituted by one alkyl group, and a phenyl group.
- Kingdom
- Organic compounds
- Super Class
- Organic oxygen compounds
- Class
- Organooxygen compounds
- Sub Class
- Carbonyl compounds
- Direct Parent
- Alkyl-phenylketones
- Alternative Parents
- Phenoxy compounds / Phenol ethers / Benzoyl derivatives / Aryl alkyl ketones / Alkyl aryl ethers / Piperidines / Beta-amino ketones / Trialkylamines / Azacyclic compounds / Organopnictogen compounds show 2 more
- Substituents
- Alkyl-phenylketone / Phenoxy compound / Benzoyl / Phenol ether / Aryl alkyl ketone / Alkyl aryl ether / Monocyclic benzene moiety / Beta-aminoketone / Piperidine / Benzenoid show 12 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- piperidines, aromatic ketone (CHEBI:4724)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Voltage-gated sodium channel activity
- Specific Function
- Tetrodotoxin-resistant channel that mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference acro...
- Gene Name
- SCN10A
- Uniprot ID
- Q9Y5Y9
- Uniprot Name
- Sodium channel protein type 10 subunit alpha
- Molecular Weight
- 220623.605 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Roghani S, Duperon DF, Barcohana N: Evaluating the efficacy of commonly used topical anesthetics. Pediatr Dent. 1999 May-Jun;21(3):197-200. [PubMed:10355012]
- Tella SR, Goldberg SR: Monoamine transporter and sodium channel mechanisms in the rapid pressor response to cocaine. Pharmacol Biochem Behav. 1998 Feb;59(2):305-12. [PubMed:9476974]
Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:42